RPG Life Sciences Q1 Results: Revenue Rises 15.8% to ₹195.7 Crore

MUMBAI — RPG Life Sciences Limited reported a 15.8% year-on-year increase in consolidated revenue from operations to ₹195.7 crore for the first quarter ended June 30, 2026, driven by market-beating performance in its domestic formulations business. The Mumbai-headquartered pharmaceutical firm filed its unaudited Q1 FY27 financial results with the BSE Limited and the National Stock Exchange of India Limited on July 28, 2026.

The company posted a consolidated net profit of ₹307.6 million (₹30.76 crore) for the April–June quarter, backed by strong operational efficiency and segment-wide growth. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) expanded 17.9% year-on-year to ₹48.0 crore, while EBITDA margin improved by 40 basis points to 24.5% compared to 24.1% in Q1 FY26.

Segment Performance Highlights Across Key Divisions

The flagship Domestic Formulations division served as the primary growth engine, recording a 14.8% revenue increase year-on-year. This outperformed the broader Indian Pharma Market (IPM) growth rate of 11.6% during the same three-month period. Strategic focus on core therapy areas, new product introductions, and enhanced sales force effectiveness supported the segment's expansion.

In addition, the Active Pharmaceutical Ingredients (API) business recorded a sharp surge of 35.6% year-on-year in revenue, driven by the restoration of full operational capacity at its manufacturing facilities. The International Formulations segment posted steady gains, growing 7.7% year-on-year for the quarter.

Milestone Achievement and Brand Growth

During the quarter, RPG Life Sciences entered the list of the "Top 50 Indian Pharma Companies" as of June 2026, ranking as the fifth fastest-growing company in the domestic market according to Pharmarack MAT June 2026 industry data.

Product-level performance remained strong across key therapy baskets:

• Naprosyn: The company's pain-management brand grew 16% during the quarter.

• Therapy Baskets: Nephrology and Rheumatology recorded double-digit growth rates.

• Industry Recognitions: The company was named "Top Nephrology Company - 2026" by India Pharma Outlook, received recognition for "Best Use of AI in Sales Force Effectiveness" by Bluetech Media, and received the "Excellence in Breakthrough Pharmaceutical Innovations" award from Network 7 Media.

Official Sources Section

Financial metrics, segment growth statistics, and executive remarks are sourced directly from RPG Life Sciences Limited's official press release filed under regulatory compliance with BSE Limited (Security Code: 532983) and National Stock Exchange of India Limited (Symbol: RPGLIFE) on July 28, 2026.

Executive Commentary

Commenting on the Q1 FY27 results and future outlook, Ashok Nair, Managing Director of RPG Life Sciences Limited, stated:

"We have started FY27 on a strong note continuing our track record of market-beating performance and growth. Our Domestic Formulations business continued to outperform the market and helped the company enter the Top 50 ranking in the Indian Pharma Market, an important milestone in our growth journey. Going forward, we remain focused on strengthening our international presence through market expansion and new customer onboarding along with scaling up our API operations that can drive the next wave of growth for us."

Why It Matters

• For Equity Investors: Outperforming the broader pharmaceutical benchmark and expanding EBITDA margins to 24.5% reflects healthy pricing power and operational discipline.

• For the Healthcare Industry: RPG Life Sciences' ascent into the Top 50 Indian pharmaceutical manufacturers highlights shifting market share toward targeted therapy portfolios like nephrology and rheumatology.

• For Supply Chain Partners: A 35.6% jump in API revenue demonstrates normalized production runs and improved capacity utilization.

Key Facts at a Glance

• Consolidated Revenue: Reached ₹195.7 crore, up 15.8% year-on-year.

• Consolidated Net Profit: Recorded at ₹307.6 million (₹30.76 crore).

• EBITDA Margin: Expanded by 40 bps to 24.5%.

• Domestic Growth: Domestic Formulations grew 14.8% vs. 11.6% for the Indian Pharma Market.

• API Growth: API business surged 35.6% as operations returned to full scale.

Frequently Asked Questions

What was RPG Life Sciences' revenue for Q1 FY27?

RPG Life Sciences reported consolidated revenue from operations of ₹195.7 crore for Q1 FY27, representing a 15.8% increase compared to ₹168.9 crore in Q1 FY26.

How did the Domestic Formulations business perform relative to the market?

The Domestic Formulations business grew 14.8% in Q1 FY27, outperforming the Indian Pharma Market (IPM) growth rate of 11.6%.

What drove the strong revenue growth in the API segment?